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ABSTRACT
Purpose To detect and characterize the aggregation of therapeutic
monoclonal antibodies in undiluted biological fluids.
Methods Fluorescently labeled subvisible IgG aggregates
formed by applying either heat stress or by pH-shift were
investigated immediately after addition to human serum, and
after 24 h. Unstressed and stressed IgG formulations were
analyzed by fluorescence single particle tracking, confocal laser
scanning microscopy and flow cytometry.
Results Unstressed formulations remained free from subvisible
aggregates in serum, whereas heat-stressed and pH-shift stressed
formulations showed dissimilar aggregation behaviors. The aggre-
gation profile of the heat-stressed formulation diluted in serum
remained practically the same as the one diluted in buffer, even
after the 24 h incubation period. The pH-shift stressed formula-
tion had strikingly smaller and more numerous subvisible aggre-
gates immediately after dilution in serum compared to buffer.
These aggregates became noticeably larger in both diluents after
24 h, but in serum they appeared to be formed by other types of
constituents than the labeled protein itself.
Conclusion These results show that subvisible therapeutic
protein aggregates may undergo changes in number, type and
size distribution upon contact with human serum. This empha-
sizes the importance of analytical strategies for monitoring
aggregation in undiluted biological fluids.
KEY WORDS confocal laser scanning microscopy . flow
cytometry . monoclonal antibody . serum . subvisible protein
aggregates . fluorescence single particle tracking
INTRODUCTION
Therapeutic proteins are an increasingly important class of
drugs. However, their inherent tendency to aggregate dur-
ing manufacture, shipping, storage and delivery remains a
problem that hinders their development and commerciali-
zation (1–4). The presence of aggregates in protein formu-
lations is undesirable, not only because of reduced
therapeutic efficacy due to loss of the active (usually mono-
meric) form of the protein, but also because it is believed
that aggregates can trigger unwanted immunological
responses once administered to patients (5–7). The develop-
ment of an immune response against a therapeutic protein
can have serious clinical consequences, such as loss of ther-
apeutic efficacy or even the neutralization of an equivalent
endogenous protein (6). Monitoring the amount and type of
aggregates present in protein formulations has become a
main concern for pharmaceutical companies and regulatory
agencies over the last few decades.
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Among the numerous types of protein aggregates, sub-
visible aggregates have received a lot of attention recently
because of their potential immunogenicity in conjunction
with the fact that they have been analytically overlooked
until recent years (3,8). Subvisible aggregates are typically
between 0.1 and 50 μm in size and in the present work they
are divided into micron- (1–50 μm) and submicron-sized
(0.1–1 μm) aggregates. Such aggregates are a particular
cause for concern because they mimic highly immunogenic
viruses and bacteria both in terms of size range and in terms
of the presence of closely spaced repetitive epitopes at their
surface (9–11). However, there remain no regulations
against the presence of subvisible particles under the size
of 10 μm in protein formulations and other parenteral
solutions.
The characterization of protein aggregates is complex
and requires the use of many different analytical techniques
(3,4,12). Until only a few years ago, subvisible aggregates
posed a particular analytical challenge, mostly due to the
lack of suitable techniques for their size range. This is now
changing with the continuing development of new analytical
techniques such as nanoparticle tracking analysis (NTA),
flow microscopy and Taylor dispersion analysis (TDA)
(13–17). However, methods to investigate subvisible aggre-
gates in serum are still lacking and very little is known about
the fate of protein pharmaceuticals and their aggregates
following administration to patients. The size and affinity
of complexes between a therapeutic IgG and its antigen
have shown to be different in buffer and serum (18), which
reinforces the importance of studying therapeutic protein
aggregates also in biological fluids.
The main obstacle that must be overcome in order to
analyze aggregates of a specific therapeutic protein in bio-
logical fluids is that such fluids contain an extremely high
amount of various proteins and other biological compo-
nents, which have a camouflaging effect for most conven-
tional analytical techniques. To overcome this problem we
covalently labeled our protein of interest (IgG) to a fluores-
cent probe (Alexa Fluor® 488) in order to make it distin-
guishable from all the other biological components. A wide
size range of protein aggregates was obtained by the indi-
vidual manipulation of two pharmaceutically relevant stress
factors: temperature and pH. Stressed and unstressed for-
mulations were then introduced in undiluted human serum
and subvisible aggregates were analyzed by three different
fluorescence-based techniques: fluorescence single particle
tracking (fSPT), confocal laser scanning microscopy (CLSM)
and flow cytometry (FCM).
fSPT is an emerging technique for sizing fluorescent
particles from about 50 nm to 1 μm. This technique com-
bines a fluorescence microscope with widefield laser illumi-
nation and an electron-multiplying charge-coupled device
camera, which enables the visualization, recording and size
measurement of fluorescent particles moving under Brow-
nian motion. fSPT has already proven to be efficient to size
submicron particles in undiluted biological fluids (19,20).
CLSM is a powerful imaging technique that manages to
eliminate out-of-focus light in areas that are thicker than the
focal plane (ca. 0.75 μm). In this work we decided to use
CLSM to monitor the aggregates in serum because this
technique removes a great percentage of the background
light coming from A488-IgG monomers, which enabled us
to have clear images of the aggregates.
FCM is a well-established technique that has the capacity
of simultaneously analyzing different parameters of individ-
ual particles at a very fast rate, ignoring all other particles
that do not meet certain chosen criteria, i.e. serum compo-
nents in our case. Even though FCM is most commonly
used for cells and particles in the micron range, the potential
of this technique for analyzing submicron particles is well-
known and it has been explored to analyze nanoparticles in
biological fluids (21–23).
This work shows that it is possible to answer some of the
questions about the fate of biopharmaceuticals upon admin-
istration to patients. Monitoring the fate of therapeutic
proteins and their aggregates in biological media may pro-
vide crucial information for drug development at various
phases and help to understand some of the adverse reactions
observed for some these drugs.
MATERIALS AND METHODS
IgG and Diluents
A recombinant human monoclonal antibody of the IgG1
subclass was used for this experiment at an initial concen-
tration of 1 mg/ml. The buffer used to formulate and dilute
the IgG contained 10 mM sodium citrate (Merck, Darm-
stadt, Germany), 5 % (w/v) sucrose (Sigma-Aldrich, Buchs,
Switzerland), pH 6.0. The buffer was filtered using a 0.22-
μm PES low binding syringe-driven filter unit (Millex™ GP,
Millipore, Ireland).
Human serum was collected from four healthy volunteers
free of medications. The serum was collected in Vacutainer
SST tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and
centrifuged for 15 min at 3000 rpm in a Beckman Coulter
Alegra X-12 centrifuge (Brea, CA, USA) to remove all the
blood cells and clotting factors. The serum samples were
stored at 4 °C for a maximum period of six hours before
being used for the experiment. The viscosity of the buffer
and serum was measured in an AR-G2 rheometer from TA
Instruments (New Castle, DE, USA) at 37 °C. The average
values obtained for buffer were 0.8 cP and for the four
collected sera were 1.23, 1.29, 1.30 and 1.34 cP. These
values were used for fSPT measurements, in order to obtain
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accurate size distributions in each diluent. The results in
serum displayed in fSPT, CLSM and FCM graphs were
chosen from a representative donor in each case.
Fluorescent Labeling
Alexa Fluor 488 carboxylic acid, N-hydroxysuccinimide
ester was obtained from Invitrogen (Merelbeke, Belgium).
The IgG labeling was performed according to the manu-
facturer’s instructions, using an IgG concentration of
10 mg/ml and a molar ratio of 4:1 (dye:IgG). A pH of 7.4
was chosen for the labeling buffer, in order to achieve
selective labeling of the amine termini. The A488-IgG was
dialyzed using a Float-A-Lyzer® G2 (Spectrum, Rancho
Dominguez, CA, USA) with a 100 kDa molecular weight
cut-off membrane to remove excess of dye and to exchange
from the labeling buffer back to the original formulation
buffer. The final A488-IgG concentration was 1 mg/ml and
the labeling ratio achieved was about 2 A488 labels per IgG.
Preparation of IgG Aggregates
The IgG aggregates were obtained by either heat or pH-
shift stress. Both labeled and unlabeled IgGs were stressed at
a concentration of 1 mg/ml. The heat stress consisted of
incubating the A488-IgG at 74 °C for 12 min and the
unlabeled IgG at 74 °C for 18 min. One ml of IgG formu-
lation was placed in 1.5-ml reaction tubes (Eppendorf,
Hamburg, Germany) and the incubation was performed
on an Eppendorf Thermomixer® R (Hamburg, Germany).
The pH-shift stress consisted of changing 5 times the buffer
pH from pH 6 to pH 1 and back to pH 6 at room temper-
ature. For each pH-shift cycle, hydrochloric acid (5 M)
(Sigma-Aldrich, Steinheim, Germany) was slowly added
drop wise to the IgG formulation in order to change the
pH from 6.0 to 1.0. The samples were then kept for 1 min at
this low pH with constant stirring at 400 rpm with a stirring
bar. Then, sodium hydroxide (5 M) (Sigma) was added drop
wise to adjust the pH back to 6.0. Stirring by itself did not
induce aggregation, according to different techniques. All
stressed samples were kept at 4 °C until further use. A488-
IgG stressed and unstressed formulations were diluted 50-
fold in either buffer or serum before fSPT, CLSM and FCM
measurements. These samples were analyzed right after the
dilution and after an incubation period of 24 h at 37 °C in a
INB 400 Memmert incubator (Memmert, Schwabach,
Germany).
Size Exclusion Chromatography (SEC)
SEC was performed on a TSK Gel 3000 SWXL column
(Tosoh Bioscience, Montgomeryville, PA, USA), using a
Thermo Separation Products Spectra System P4000
gradient pump (Thermo Scientific, Breda, The Netherlands),
a Waters 717 plus autosampler (Waters, Milford, MA, USA)
and a Spectra-Physics UV150 UV detector (Spectra-Physics,
Irvine, CA, USA) at a 280 nm wavelength. The data was
collected using ADChrom software version 3.5 (Agilent Tech-
nologies, Santa Clara, CA, USA). Fifty μl of each sample was
injected and separation was performed at a flow rate of
0.5 ml/min. The running buffer was composed of 25 mM
phosphate, 125 mM arginine, 0.025 % (w/v) sodium azide at
pH 7 (Sigma-Aldrich, Steinheim, Germany).
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis
SDS-PAGE was performed with a Biorad Mini-Protean 3
module (Bio-Rad, Hercules, CA, USA), as described previ-
ously (24). Briefly, a 4–20 % linear gradient Tris–HCl Ready
Gel from Bio-Rad was run under non-reducing and reducing
(sample buffer containing 5 % (v/v) β-mercaptoethanol) con-
ditions at 150 V at room temperature. The bands were
detected by Coomassie Brilliant Blue R-250 staining and the
gel was scanned with a Bio-Rad GS-800 densitometer and
Quantity One software.
Nanoparticle Tracking Analysis
NTA measurements were performed with a NanoSight
LM20 (NanoSight, Amesbury, United Kingdom), equipped
with a sample chamber with a 640-nm laser and a Viton
fluoroelastomer O-ring, as described previously (15). Briefly,
the samples were injected in the sample chamber with sterile
BD Discardit II syringes (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) until the liquid reached the tip of
the nozzle. The software used for capturing and analyzing
the data was the NTA 2.0 Build 127. The samples were
measured for 40 s with manual shutter and gain adjust-
ments. Six measurements of each sample were performed
and the mean was obtained. The error shadows represent
the standard deviations between the measurements. Stressed
formulations were diluted 50-fold with buffer before each
measurement.
Light Obscuration (LO)
LO measurements were performed on a PAMAS SVSS
system (PAMAS GmbH, Rutesheim, Germany) equipped
with a HCB-LD-25/25 sensor and a 1- ml syringe. Each
sample was measured three times, with each measurement
consisting of a pre-run volume of 0.3 ml followed by three
runs of 0.2 ml at a flow rate of 10 ml/min. The final results
are a mean of the three runs and the error bars represent the
standard deviation between them. Stressed formulations
were diluted 50-fold with buffer before each measurement.
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Fluorescence Single Particle Tracking
The fSPT technique was recently described in detail by
Braeckmans et al. (19). The measurements were performed
with an inverted epi-fluorescence microscope (Nikon
TE2000E, NIKON BELUX, Brussels, Belgium) equipped
with a Nikon Plan Apochromat 100× NA1.4 oil immersion
objective lens, a 100 mW Calypso 491 nm laser (Cobolt,
Solna, Sweden), an electron-multiplying CCD camera (Cas-
cade II:512; Roper Scientific, Tucson, AZ) and the results
were processed with Nikon Elements R imaging software
combined with custom build software. Each measurement
consisted of the recording and analysis of 10 or 20 videos of
the same sample, with the number of videos depending on
the amount of aggregates in each sample. Each video was
recorded at 35 frames per second for 5 s only in order to
minimize photobleaching. At least 3 measurements from
each stressed formulation were performed in buffer and 1
measurement for each blood donor.
Confocal Laser Scanning Microscopy
CLSM images were obtained using the Argon blue laser
(488 nm) from a Bio-Rad Radiance 2100 MP confocal laser
scanning system (Bio-Rad, Hercules, CA, USA) equipped
with a Nikon Eclipse TE2000-U inverted fluorescence mi-
croscope and a 60x A/1.4 oil Nikon objective (Nikon,
Tokyo, Japan). LaserSharp 2000 v6.0 software (Bio-Rad,
Hercules, CA, USA) was used for image acquisition and
Adobe Photoshop CS5 (Adobe, San Jose, CA, USA) for
image processing. A 4 μl drop of each sample was placed
on a well of a 24 well Greiner SensoPlate (Greiner Bio-One,
Alphen a/d Rijn, The Netherlands), covered with a glass
coverslip (Menzel-Gläser, Braunschweig, Germany) and im-
mediately analyzed. Triplicates of each sample in buffer and
serum from each donor were analyzed. The scans were
made at a distance of about 10 μm from the glass surface,
with the same settings for all submicron aggregates in both
diluents. The settings had to be individually adjusted for
each micron-sized aggregate in order to obtain sharp
images. A rough estimation of the amount of aggregates
bigger than ca. 5 μm/ml (i.e. aggregates that had a defined
shape) was obtained by extrapolating the average amount of
these aggregates present in each well (4 μl). At least 3 wells
from each stressed formulation in buffer and serum were
considered for these estimations.
Flow Cytometry
FCM was performed with a BD FACSCanto II flow cytom-
eter (Becton, Dickinson and Company, Franklin Lakes, NJ,
USA). The data was collected with the BD FACSDiva 6.2
software and processed with the FlowJo 7.6.4 software (Tree
Star, Ashland, OR, USA). The samples were analyzed with
the lowest flow rate and the window extension was set to the
minimum value (0.5) in order to minimize coincidence of
particles in front of the detectors. The measurements were
stopped after 2 min of data collection so that the number of
events could be compared between samples. At least 3
measurements from each stressed formulation were per-
formed in buffer and 1 measurement for each blood donor.
The events were detected by the 530/30 (FITC) and 488/
10 (side scatter) photomultiplier tubes (PMTs). Given that
most of the aggregates present in our stressed formulations
were in the submicron range, the PMT voltages were ad-
justed for this size range. A threshold of 300 was set for the
FITC-PMT in order to eliminate background events from
serum.
Yellow-green fluorescent (excitation 505 nm/emission
515 nm) polystyrene standards of 200, 500 and 2000 nm
(Invitrogen, Merelbeke, Belgium) were used to optimize
PMT voltages for submicron particles. These beads were
also used to obtain an approximate size calibration for the
protein aggregates, by direct comparison of side scatter
intensity and by pulse width calibration (Supplementary
Material) (22,25). These two approaches gave similar
aggregate size averages.
RESULTS
A first step in any study involving fluorescently labeled
proteins is to identify if and how the presence of the fluo-
rescent probe affects the behavior of the protein. In this case
the effect on the aggregation behavior was evaluated.
Labeling Effect on Protein Aggregation
In this study Alexa Fluor® 488 (A488) was covalently linked
to a humanized monoclonal antibody of the IgG1 subclass
(IgG). Incubation at a high temperature (heat stress) and
short exposures to low pH (pH-shift stress) were the two
stress methods used to obtain subvisible aggregates of both
A488-IgG and unlabeled IgG. The effect that this fluores-
cent label had on the aggregation profile of this protein was
monitored by complementary methods covering a broad
size range: SEC, NTA and LO (Fig. 1).
These results show very similar aggregation profiles be-
tween the A488-IgG and unlabeled IgG, for both stressed
and unstressed formulations. SEC results show approxi-
mately the same amount of monomer loss and the same
pattern of aggregation after the stresses. The 0.2 min left-
shift observed in all the SEC chromatograms of the A488-
IgG is most likely associated with the slightly increased
molecular weight caused by the fluorescent label. NTA
and LO results show small differences in size distribution
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and particle counts between the A488-IgG and the unla-
beled IgG aggregates, but they are within the errors associ-
ated with the stress methods and analytical procedure.
Aggregation Profile Characterization
The SEC chromatograms in Fig. 1 show that pH-shift
stress induced a large monomer loss associated with the
formation of dimers, trimers and larger oligomers. Heat
stress led to a slightly smaller monomer loss and the
formation of larger oligomers. It is important to notice
that with SEC, aggregates larger than 500 kDa either
pass through the void volume of the column and appear
as a single peak (eluting at ca. 12 min) or they become
trapped in the column due to their large size or non-
specific binding (26). In fact the protein recovery of the
stressed samples was about 70 % and 50 % for the pH-
shift and the heat stress samples, respectively. In order
to obtain the size distribution of the larger oligomers,
NTA and LO were used.
From the NTA results, it is clear that pH-shift stress
induced a slightly higher amount and a more polydisperse
distribution of submicron aggregates than heat stress. The
NTA size averages of the pH-shift and heat-stressed formu-
lations were about 280 nm and 180 nm, respectively. The
LO results show a much higher amount of micron-sized
aggregates induced by heat than by pH-shift stress. The
main reason for the apparent absence of aggregates between
500 nm and 1 μm, when comparing NTA and LO results, is
the 102 fold difference in the concentration range detected
Fig. 1 Aggregation profile of A488-IgG and unlabeled IgG formulations, after pH-shift and heat stresses. The top row graphs are chromatograms obtained
by SEC with UV absorption detection at 280 nm. The middle row graphs show the aggregate size distribution obtained by NTA (submicron range) and the
lower row graphs the distribution obtained by LO (micron range). The NTA and LO graphs contain standard deviations, represented by shadows and error
bars, respectively.
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by these techniques. This means that most aggregates of
these stressed formulations are in the submicron range.
Both stressed formulations were analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) in order to detect the presence of covalent aggre-
gates (Fig. 2).
Under non-reducing conditions all the formulations show
a pronounced band at around 150 kDa, which corresponds
to the molecular weight of IgG monomers. It is also possible
to distinguish a clear band at the top of the heat stress lane,
which corresponds to covalent aggregates that due to their
large size could not enter the gel matrix and therefore
deposited on top of the gel. The lack of band at the top of
the pH-shift lane suggests that the aggregates formed by this
stress method were not covalent and therefore dissociate
under the denaturing conditions caused by the presence of
SDS.
Under reducing conditions the intramolecular disulfide
bonds of the IgG monomers break, originating two
bands at around 25 kDa and 50 kDa, which correspond
to the light and heavy chains, respectively. Moreover,
the absence of a heat-stressed aggregate band (visible on
top of the non-reducing gel) under reducing conditions
substantiates the covalent, disulfide bond mediated na-
ture of these aggregates.
Strategy to Monitor Subvisible Aggregates in Serum
In order to monitor the aggregation profile of A488-IgG in
serum, unstressed, heat-stressed and pH-shift stressed for-
mulations were diluted at 1:50 (v/v) ratio in buffer and
human serum, and analyzed by fSPT, CLSM and FCM.
The final IgG concentration after dilution in this experiment
(0.02 mg/ml) is in the same order of magnitude as typical
concentrations reached by therapeutic IgGs administered
intravenously to humans (27,28). The samples were ana-
lyzed immediately after dilution and after an incubation
period of 24 h at 37 °C.
Fluorescence Single Particle Tracking
fSPT measurements of A488-IgG stressed formulations in
buffer and serum are shown in Fig. 3. The unstressed
formulation did not contain measurable amounts of submi-
cron aggregates in either buffer or serum, even after the
incubation period at 37 °C.
The fSPT aggregate size distributions in buffer are con-
sistent with the ones obtained by NTA, with size averages
for the pH-shift and heat-stressed formulations of 292 nm
and 137 nm, respectively (Table I). The differences in size
distribution smoothness given by these techniques are most-
ly due to their different approaches of data handling, as
described previously (15,19).
The size average of the aggregates in the pH-shifted
formulation considerably decreased after dilution in serum,
from 292 nm to 110 nm. In fact, the amount of aggregates
observable through the microscope of this device was strik-
ingly higher in serum right after dilution, but most of them
were actually too small and faint for the software to track
them properly. This suggests that most of these aggregates
were smaller than 50 nm and/or composed of a mixture of
A488-IgG and serum components, which would have
resulted in aggregates with lower fluorescence intensity.
Surprisingly, after the incubation period of 24 h at 37 °C
most aggregates in buffer were micron-sized, i.e. beyond the
range of fSPT to determine their size. In serum, most of the
pH-shift aggregates also became bigger (ca. 460 nm), but
not as much as in buffer.
In contrast, the heat-stressed aggregates showed only a
small size average decrease when diluted in serum, from
137 nm to 102 nm. However, given that the error of these
measurements is about 30 nm, the decrement is not note-
worthy. These aggregates seemed to be stable after the 24 h
incubation period in both buffer and serum.
Confocal Laser Scanning Microscopy
Even though CLSM is primarily used for imaging optical
sections of micron-sized structures, the lower size limit of
this technique can go beyond the typical optical microscope
resolution (ca. 200 nm) if the particles analyzed are bright
enough. In this study, while submicron aggregates were
captured as mere dots, micron-sized aggregates displayed
well-resolved shapes (Fig. 4). This enabled us to also monitor
possible morphology and size changes of micron-sized
aggregates in serum. It was not possible to distinguish any
Fig. 2 SDS-PAGE gel of unstressed (Unst), heat-stressed (Heat) and pH-
shift (pH) stressed formulations under reducing and non-reducing
conditions.
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aggregates for the unstressed formulation in either buffer or
serum, even after the incubation period at 37 °C.
The CLSM images show clear differences at time 0 h
between the pH-shifted submicron aggregates in buffer and
in serum. It is possible to observe that these aggregates
became smaller and more numerous immediately after be-
ing diluted in serum. After 24 h at 37 °C these aggregates
became visibly larger in both diluents, but in this case there
were no obvious differences between them. On the other
hand, heated submicron aggregates did not seem to change
once diluted in serum, even after the incubation period.
These observations are consistent with the size distributions
obtained by fSPT.
The micron-sized pH-shift aggregates appear to have
different morphology from the heat-induced aggregates.
pH-shift seems to induce the formation of aggregates resem-
bling clouds or popped balloons, whereas heat-induced
aggregates appear to be assemblies of compact smaller units.
The morphology and amount (Table I) of these micron-
sized aggregates seem to remain approximately the same
in buffer and in serum, even after the incubation period.
Flow Cytometry
Fluorescence vs. side scatter (SSC) plots of stressed formula-
tions in buffer and serum are shown in Fig. 5. The unstressed
formulation gave less than the minimum amount of display-
able events for both diluents and both incubation times.
For submicron particles, SSC proved to be the most
accurate indicator of particle size, whereas fluorescence
intensity served as the selective parameter to distinguish
A488-IgG aggregates from other serum components. An
approximate calibration with fluorescent standard beads
suggested that events with SSC signal of 102 are about
200 nm, 103 are about 500 nm and 104 are micron-sized
(Supplementary Material). Although light scatter also
depends on the refractive index of the particles, in agree-
ment with fSPT results FCM indicates that most aggregates
present in both stressed formulations at time 0 h are about
200 nm. All plots at time 0 h display a linear positive
correlation between fluorescence and SSC, indicating that
as the size of the aggregates increases, their fluorescence also
increases, as expected.
Both stressed formulations show the same dot distribution
in serum as in buffer at time 0 h, but the number of events of
the pH-shifted and heated formulations in serum is 3 and 2
times lower, respectively (Table I). This occurrence was also
observed for fluorescent standard beads, in which the number
of events was about 2 times lower in serum than in buffer.
Serum seems to have some sort of a masking effect for this
technique, most likely caused by its translucent properties.
The presence of serum components might lead to secondary
scattering and absorption of both the incoming light beam
and the scattered or emitted light from the aggregates, even-
tually resulting in a smaller amount of particle counts.
After the 24 h incubation period, the heat-stressed plot
does not suffer any significant changes in both the position
of the main population and the number of events (Table I).
On the other hand, the main population of the pH-shifted
Fig. 3 fSPT measurements of stressed A488-IgG formulations in buffer and in serum, immediately after dilution and after a 24 h at 37 °C.
Table I fSPT Mean Size Distribution and Average Aggregate Concen-
trations from CLSM and FCM Measurements of Stressed A488-IgG For-
mulations in Buffer and Serum, Immediately After Dilution and After an
Incubation Period of 24 h at 37 °C. The Errors Represent the Standard
Deviation Between 3 Different Dilutions in Buffer or Between the Meas-
urements in Serum of the Different Blood Donors
Analytical method Sample pH-shift Heat
fSPT mean (nm) Buffer 0 h 292±47 137±38
Serum 0 h 110±32 102±27
Buffer 24 h N/A 150±46
Serum 24 h 463±81 112±41
CLSM [(particles>5 μm)
×103/ml]
Buffer 0 h 10±2 33±7
Serum 0 h 12±3 40±5
Buffer 24 h 9±3 35±4
Serum 24 h 11±3 35±7
FCM (counts×103) Buffer 0 h 12±2 11±2
Serum 0 h 4±1 6±2
Buffer 24 h 30±8 10±3
Serum 24 h 90±42 5±2
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formulation shows a clear shift towards higher values of SSC
and fluorescence in buffer after the incubation period, which
confirms the formation of larger aggregates. Surprisingly, in
serum, the main population shows a shift towards higher SSC,
but the fluorescence signal remains the same. The different
position of the main population in the 24 h pH-shift plots
Fig. 4 CLSM images of stressed A488-IgG formulations in buffer and serum, immediately after dilution (upper row) and after an incubation period of 24 h
at 37 °C (lower row). A representative micron-sized aggregate is shown on the right upper corner of each image (same size scale).
Fig. 5 Fluorescence vs. side scatter FCM plots of stressed A488-IgG formulations in buffer and serum, immediately after dilution (upper row) and after an
incubation period of 24 h at 37 °C (lower row). The dot density color gradient goes from blue (sparse) to red (very dense).
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suggests that the large aggregates formed in serum are some-
how different from the ones formed in buffer. Moreover, the
number of events after the incubation period increased and it
is about 3 times higher in serum than in buffer (Table I).
DISCUSSION
According to the SDS-PAGE results (Fig. 2), heat stress led to
the formation of covalent IgG aggregates, whereas pH-shift
stress did not. The nature of these covalent bonds is probably
disulfide mediated, as the aggregates were not detected by
SDS-PAGE under reducing conditions. Both heat and pH-
shift stress conditions are expected to induce at some degree of
unfolding, but through distinct driving forces. Protein unfold-
ing normally results in the exposure of hydrophobic regions
and eventually, in the case of IgG, free cysteins (29). Protein
unfolding is normally followed by aggregation, mostly medi-
ated by hydrophobic effects (30). In the case of heat stress, the
formation of intermolecular disulfide bonds is probably facil-
itated by the high temperature, either by two free cysteins or
by thiol-disulfide exchange. Disulfide bonds have smaller dis-
sociation energies than other covalent bonds in the protein
and are susceptible to breakage under the reducing conditions
used in SDS-PAGE (31). On the other hand, for the pH-shift
sample, the low pH prevents the dissociation of thiol groups
and consequently the formation of disulfide bonds is hindered
(32). This may explain the lack of covalent aggregates at the
top of the gel under non-reducing conditions for the pH-shift
sample.
The effect that a fluorescent label and a stress factor may
have on the aggregation profile of therapeutic proteins, and
how this will affect their fate in serum, may vary significantly
according to the type of protein, label, stress factor and
stress conditions (33–35). Therefore, the results obtained in
this study should not be generalized for other proteins or
fluorescent labels and a case-by-case approach should be
followed.
From all the fluorescent dyes previously tested for this
study (Alexa Fluor® 488, 546, 555, 594 and 700), A488 was
the one that least changed the aggregation behavior of this
IgG for the chosen stress methods (data not shown). How-
ever, during optimization studies we noticed that the heat-
induced aggregation kinetics of the A488-IgG was slightly
different from the unlabeled IgG. At the same temperature,
the evolution of the aggregate size distribution was the same,
but the A488-IgG had the tendency to arrive faster to these
aggregation states. Thus, in order to obtain stressed formu-
lations of labeled IgG with a similar aggregate size distribu-
tion as the unlabeled IgG, the heating time of A488-IgG was
a few minutes shorter than the one used for unlabeled IgG.
Nevertheless, a comparable aggregate size distribution for
heated A488-IgG and unlabeled IgG was achieved.
Interestingly, heat-stressed aggregates turned out to be
the most measurably stable aggregates in both serum and
buffer throughout the incubation period. Therefore, even
though the presence of the fluorescent label led to a slightly
lower degree of stability of this IgG, this does not seem to
have significant consequences for the aggregation state of
this protein in serum.
The subvisible aggregates of the pH-shifted formulation
were very unstable in serum. The size reduction immedi-
ately after dilution in serum was consistently shown by fSPT
and CLSM. FCM results did not clearly show this size
reduction, most probably because most of them fall under
the detection limits of this technique. This size reduction
was quite surprising, since in our previous work, in which we
tested the potential of fSPT to monitor glutaraldehyde
cross-linked covalent aggregates in biological fluids, a slight
size increase in serum and plasma was observed, presumably
because of adsorption of serum components to these aggre-
gates (20). In the present work, pH-shift aggregates not only
became smaller but also much more numerous immediately
after dilution in serum. Also the heat-stressed aggregates
showed a slight size decrease in serum according to fSPT,
although to a lesser extent, which may be due to the partly
covalent nature of these aggregates (Fig. 2). These results
suggest that something more complex is happening with
non-covalent IgG aggregates upon dilution in serum.
The appearance of a very large amount of submicron
aggregates in the pH-shifted formulation immediately after
dilution in serum was remarkable. Such a high amount
suggests that these aggregates derived not only from preex-
isting aggregates but probably also from unstable mono-
mers. At extreme pH’s proteins are heavily charged, which
eventually leads to chemical changes and at least partial
unfolding of every monomer in solution (30). When the
pH is restored to the original formulation buffer, it is likely
that some of these monomers remain partially unfolded.
Heat stress also leads to chemical changes and the formation
of unfolded states, but by different processes (36). Thus, it is
possible that in our case the heat-induced unfolded states
were more reversible than the ones caused by pH-shift
stress. The presence of unstable pH-shifted monomers and
aggregates could then have triggered a multitude of path-
ways in serum that could have led to the formation of these
numerous small submicron aggregates.
The formation of larger subvisible aggregates in both
serum and buffer after the incubation period for the pH-
shift formulation was also surprising. The aggregation pro-
file of these aggregates had proven to be stable for several
weeks, but something as trivial as a dilution with the same
buffer induced an aggregate-size increase. This occurrence
shows how complex and unpredictable aggregated species
can behave. This A488-IgG aggregate size increase upon
dilution after 24 h was confirmed with unlabeled IgG and it
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also happened at 4 °C, but to a lesser extent (data not shown).
These results support the concerns about on the one hand
analytical techniques for protein aggregates involving dilu-
tions, such as SEC and field flow fractionation, and on the
other hand changes that may occur after e.g. intravenous
administration which is followed by rapid dilution (37).
FCM results suggest that the large pH-shift aggregates
formed in serum after the incubation time had a different
composition from the ones in buffer. The observation that
large aggregates formed in serum were considerably less
fluorescent than the ones formed in buffer, led to the hy-
pothesis that the former are composed of a mixture of A488-
IgG and other, non-fluorescing serum components. Adsorp-
tion of serum proteins to nanoparticles and other biological
materials upon dilution in a physiological environment has
been reported (38). In fact, pure self-association of A488-
IgG molecules in such complex environments is highly un-
likely, since specific binding between monomers of the same
IgG is not to be expected.
Immunoglobulins are the second most abundant pro-
tein in blood and the amount of physiological pathways
in which IgG can be involved is enormous (39). Thus,
identifying the components responsible for the pH-shift
aggregate changes in serum can be very challenging.
Nevertheless, we decided to briefly investigate if human
serum albumin (HSA) or complement factor C1q could
be involved in these changes. We chose these proteins
because: HSA is the most abundant protein present in
blood and is known for being a carrier for several
proteins; C1q is known to bind to IgG only when it is
aggregated, in order to activate the classical pathway of
the complement system (39,40). The pH-shift formula-
tion was diluted in buffer containing these proteins at
their approximate serum concentration (HSA—40 mg/
ml; C1q—0.1 mg/ml), but no conclusive results were
obtained (data not shown) (39,41). It is likely that a
combination of several serum components is required to
induce the changes observed in serum. This underscores
the need for more research to understand the causes of
the observed changes in the subvisible aggregate profile
in serum.
The fact that micron-sized aggregates of both stressed
formulations did not seem to change throughout the entire
experiment is intriguing. Nevertheless, small changes in this
size range could have been overlooked by CLSM. There-
fore, all samples were also analyzed by FCM with settings
optimized for the micrometer range, but no clear differences
in particle counts, fluorescence intensity or scattering signal
were observed (data not shown). Altogether, it seems that
pH-shift induced micron-sized aggregates are more stable
than submicron aggregates in serum.
The only condition stipulated by the United States Phar-
macopeia (USP) for the presence of subvisible particles in
therapeutic protein formulations as well as other parenteral
solutions (standard <788>) states that particles >10 μm
should be controlled below 6000 particles/container and
particles >25 μm below 600 particles/container. However,
there are no studies that would support the idea that sub-
micron and micron-sized aggregates are less immunogenic
than visible precipitates (>50 μm) (8). In fact, our stressed
samples would have passed USP standards and yet most of
the product is under the form of potentially immunogenic
aggregates, which subsist after dilution in serum.
CONCLUSIONS
The fate and behavior of subvisible IgG aggregates in bio-
logical fluids has been investigated. Whilst unstressed IgG
remains apparently unchanged in serum, i.e. it does not
spontaneously aggregate, certain aggregates of the same
protein do change. Aggregates formed by pH-shift appear
particularly susceptible, whereas the ones formed by heat
stress seem to be stable. These results indicate that the
aggregation profile of therapeutic proteins may drastically
change once the formulation is administered, emphasizing
the importance of analytical strategies for monitoring aggre-
gation in undiluted biological fluids.
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